Table 1.
Patient characteristics.
| Patient | Age (years) | Sex (M/F) | Müller scoreb | SPT peanut (mm) | Subjective eliciting dose (ED) (mg) | Objective ED (mg) | CAP peanut (kU/L) |
|---|---|---|---|---|---|---|---|
| N01 | 41 | F | 2 | 3+ | 10 | – | 1.7 |
| N02 | 37 | M | 4 | 3+ | 0.1 | 300 | 44 |
| N03 | 45 | M | 2 | 4+ | 100 | – | 1.8 |
| N04 | 50 | F | 3 | 4+ | 10 | 10 | 12 |
| N05 | 35 | F | 4 | 4+ | 0.1 | – | 85 |
| N06a | 27 | F | 2 | 4+ | 4 | 40 | 12.8 |
| N07a | 42 | M | 3 | 5+ | Not known | 300 | 42.7 |
| N08 | 24 | M | 1 | 4+ | 100 | >3,000 | 1.9 |
| N09 | 24 | F | 3 | 3+ | Not known | >3,000 | 1 |
| N10a | 18 | F | 3 | 4+ | 300 | 1,000 | >100 |
| N11 | 32 | F | 2 | 4+ | 10 | 3,000 | No data |
| N12a | 27 | M | 3 | 5+ | 0.1 | 1,000 | 66 |
| N13 | 25 | M | 1 | 3+ | 10 | – | 11.2 |
| N14a | 26 | F | 2 | 4+ | 0.1 | 100 | 9.7 |
| N15 | 34 | F | 2 | 4+ | 40 | 12,000 | 1.55 |
Age, sex, Müller score, skin prick test (SPT), results of double-blind placebo-controlled food challenge (DBPCFC), and specific IgE per peanut-allergic subject.
aSubjects that visited a second time.
bMüller score 0: symptoms oral cavity, 1: symptoms of the skins and mucous membranes 2: gastro-intestinal symptoms, 3: respiratory symptoms, 4: cardiovascular symptoms.
SPT (mm). Diameter of 3 mm (3+) is considered positive. All patients underwent a DBPCFC, subjective, and objective effective doses are displayed.